Clinical Trial Search

Primary: Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score — 39.41; 29.50; 23.60 units on a scale

Primary: Vocal Tremor Scoring System (VTSS) — 0.57; 0.57; 1; 0.43 units on a scale

Primary: Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor — 12.91; 13.49; 12.43; 9.35 percentage of voice signal with tremor — p=0.0216

Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants

Primary: Regions With fMRI Differences Between ET and Controls — 139; 93; 85; 74 Number of Activated Voxels

Primary: Voice Assessment During First Visit — 0.045; 0.17; 0.13; -0.47 decibel

Primary: Change in Tremor Rating Scale (TRS) Compared With Baseline. — 2.4; -0.2; 6.7; 3.6 units on a scale

Primary: Normalized Accelerometric Tremor Power, Dominant Hand, 80min After Administration, Weighted Condition — 0.669; 0.798 ratio — p==0.345

Primary: Evaluate the Occurrence and Severity of Treatment Emergent AEs. — 13; 9; 2; 2 participants

Primary: Adverse Response to rTMS — 0; 0 Participants

Primary: Tremor Amplitude — 127; 104; 150; 100 cm/s^2

Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale

Primary: Digital Spirography — 1.04; 1.00 millimeters of tremor amplitude

Primary: Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb) — -0.47; 0.07 degree — p=0.144

Primary: Stage 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 12.0; 20.0; 0; 0 percentage of participants

Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025

Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005

Primary: Mean TRS (Tremor Rating Score) — 26.6; 27.6 units on a scale

Primary: Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS — 2.8; 0.9 change in score on a scale

Primary: Tremor Motor Score - Clinical Rating Scale for Tremor (CRST Part A (Upper Extremity) + Part B) Percent Change From Baseline — 46.9; -0.1 Percent Change from Baseline…

Primary: Symptom Severity — 28.0; 18.6; 14.2; 12.3 score on a scale — p=0.01

Primary: Change From Baseline Compared to Placebo in TETRAS Performance Subscale Part 4 Upper Limb Tremor Score on Day 29 — -2.31; -1.24 score on a scale — p=0.0491

Primary: Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist — -0.25; -0.46 degrees of arc

Primary: Part A: Change From Baseline in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 7 — 4.36; -0.69 score on a scale

Primary: Tremor Model Accuracy — 24; 21 Normalized RMSE (%)

Primary: Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo — -6.3; -5.8; -6.7; -7.5 score on a scale

Primary: Clinical Rating Scale for Tremor (CRST) — 18.39534884; 13.97674419; 14.58139535 score on a scale — p=<0.01

Primary: Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B — 1; 1; 1.009; 0.901 normalized score on a scale

Primary: Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 (Upper Limb) Total Score on Day 91 in the Monotherapy Cohort…

Primary: Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer…